Why is Auna stock dropping today?

Auna SAA ADR stock fell 9.2% to $4.91 after revising its 2026 profitability outlook, citing higher cancer diagnosis costs in Colombia. The company maintained its revenue growth target but saw a sell-off amid broader market declines. The stock dropped to a session low of $4.55, nearing its 52-week low of $4.09.

Original reporting
Published Oct 22, 2026, 3:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 3:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$AUNA
Bearish
high confidence
Mentioned
$AUNA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AUNABearishHigh
01

Why it matters

The guidance revision is the primary catalyst for the stock's decline, overriding other market factors.

02

Market read

Auna's ADR fell 9.2% after a surprise profitability outlook downgrade, presenting a short‑term trading opportunity.

03

What to watch

Strong revenue growth in Mexico and stable capex may cushion the earnings hit.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Auna's guidance cut follows higher-than-expected cancer treatment costs in Colombia, while broader markets were down on tech earnings and oil price spikes.

Company-level read

Ticker impact

$AUNABearishHigh confidence
Context

Auna disclosed a steep downward revision to its FY2026 profitability outlook, triggering a 9.2% drop in its ADR price.

Expected impact

likely continued downward pressure as investors price in lower earnings expectations

Evidence & confidence

The new guidance is a primary, material disclosure causing a sharp price move; no mitigating factors were mentioned.

Market effects

May weigh on other Latin American healthcare operators as investors reassess earnings outlooks.

Contributes to broader weakness in U.S. equities, especially health‑care stocks.

Limited to regional and sector peers; no global macro impact.

Counterpoint

If the cost pressure is truly temporary, the stock could rebound on a short‑cover rally.

Key entities

  • Auna SAA ADR

    Latin American healthcare operator

Related articles

$AUNAMed

Auna S.A. (AUNA) Stock Falls on Q3 2026 Earnings

Auna S.A. (AUNA) reported Q3 2026 revenue of $384.7M, up 19.4% YoY, with net income falling 57.4% to $5.9M. Operating cash flow rose 38.9% to $77.6M. Insiders made 6 purchases and 1 sale in the past 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing positions.

$AUNAMed

AUNA S.A. (AUNA): Financial results for Q3 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro

$AUNAMed

Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.

$AUNAMed

Auna Q2 Earnings Call Highlights

Auna reported Q2 revenue growth in Mexico (4% YoY), Peru (8%), and Colombia (13%), but adjusted EBITDA varied. Mexico's EBITDA declined 16% YoY due to investments, while Peru's was flat due to billing penalties. Colombia's EBITDA fell 12% YoY but rose 18% sequentially. The company reaffirmed its full-year guidance, expecting 12% FX-neutral revenue growth and adjusted EBITDA growth toward the low end of its 10-14% target range, excluding Peru's billing penalties. Cash flow and leverage improved,